Didivir 200 mg / 300 mg FC tablets
PDF Leaflet Revision Date: 13 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV-1 infections and pre-exposure prophylaxis (PrEP) in HIV-negative adults.
Dosage (summary)
One tablet daily for adults.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding due to potential HIV transmission.
Key Drug Interactions
- Nephrotoxic medications
- Ledipasvir/sofosbuvir
Contraindications
- Hypersensitivity to components
- Creatinine clearance < 60 mL/min for PrEP
- Creatinine clearance < 50 mL/min for HIV treatment
- Pregnancy and breastfeeding
Common side effects
- Nausea
- Diarrhoea
- Headache
- Fatigue
Counselling Points
- Adhere strictly to dosing schedule.
- Monitor for signs of lactic acidosis.
- Regular HIV testing every 3 months for PrEP users.
Serious warnings
- Lactic acidosis
- Severe hepatomegaly
- Risk of hepatitis B exacerbation upon discontinuation
Important Disclaimer
The Didivir 200 mg / 300 mg FC tablets professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
